Community Direct DX, Scienetix, and Advanta Genetics R&D Merge to Form OSPRI, a Vertically-Integrated Molecular Testing Platform

The merger of Community Direct DX, Scienetix, and the R&D division of Advanta Genetics to form OSPRI represents a significant advancement in molecular diagnostics by creating one of the world's first fully vertically-integrated PCR testing platforms. This consolidation addresses critical barriers in infectious disease detection by combining complementary expertise to deliver an end-to-end solution that reduces both cost and complexity for healthcare providers. The $30 million strategic funding from Catalio Capital Management underscores the commercial viability and growth potential of this integrated approach to diagnostics.

OSPRI's platform specializes in polymerase chain reaction-based infectious disease detection, serving multiple healthcare segments including women's health, primary care, urgent care, urology, hospitals, and clinical reference laboratories. The company's technology achieves remarkable improvements: 20-50% reduction in overall testing costs, 50-70% decrease in testing time and workflow steps, up to 4x increase in testing capacity, and reduced lab errors through simplified workflows. These advancements are particularly important given that PCR testing, while foundational for infectious disease detection, has historically been limited by cost and complexity barriers that kept it out of reach for many providers.

The scientific leadership team, including Dr. Rahul Sharma as Chief Science Officer, Dr. Sadia Almas as Chief Innovation Officer, and Dr. Alaina Vincent as Chief Clinical Officer, brings extensive expertise to drive continued innovation. OSPRI's comprehensive menu includes 80+ PCR tests covering 250+ pathogens and antimicrobial resistance genes, with customized assays tailored to provider specialty and patient population needs. The company's production capabilities have grown exponentially from limited menu offerings to delivering over 40,000 tests per day with multilayered quality control, demonstrating both volume scalability and reliability improvements.

Built on a legacy of innovation dating back to 2015, OSPRI unites the complementary strengths of its founding entities. Community Direct DX has launched over 60 labs nationwide, Scienetix brings deep expertise in molecular bioengineering, and Advanta R&D has led advancements in high-resolution genomics while contributing to national public health initiatives. This merger enables OSPRI to provide not just assay development but complete solutions covering manufacturing, lab buildout, revenue cycle management, and regulatory support, empowering providers to operate high-complexity labs in-house with greater speed, accuracy, and financial control.

Over the next 12-24 months, OSPRI plans to expand its R&D team by 40% and grow commercial operations by 25% to meet increasing demand. Headquartered in McKinney, Texas, the company currently serves clients across 20 states and multiple clinical specialties. The formation of OSPRI represents a strategic response to the growing need for accessible, high-quality diagnostic testing that enables better, faster care for more patients by equipping providers with the tools they need to lead in infectious disease management.